Moreover, we confirmed that mice treated with anti-PD-1 blocking monoclonal antibody developed clinically and histopathologically severe IMQ-induced psoriasis-like dermatitis compared to control mice treated with isotype IgG2a control (Ctrl) antibody (Supplemental Fig. 2A–E). This evidence concerns the gene PDCD1 and skin disorder.